GPN Vaccines secures $18 million in Series B led by Forepont Capital, Kern Capital and Shearwater Capital

Jun 07, 2024•about 1 year ago

Amount Raised

$18 Million

Round Type

series b

AdelaideBiotechnology

Investors

Shearwater CapitalKern CapitalForepont Capital

Description

Adelaide-based biotechnology company GPN Vaccines has secured $18 million in an oversubscribed Series B1 investment round co-led by Forepont Capital, Kern Capital, and Shearwater Capital. The funding will enable GPN Vaccines to continue the clinical evaluation of Gamma-PNTM, invest in a pipeline of new vaccine opportunities, and position the company for its next stage of development.

Company Information

Company

GPN Vaccines

Location

Adelaide, South Australia, Australia

About

GPN Vaccines is an Adelaide-based biotechnology company founded in 2017. The company is focused on developing a novel, whole-cell vaccine to provide broad-spectrum protection against streptococcus pneumoniae, a bacterial pathogen responsible for illnesses such as sinusitis, life-threatening pneumonia, middle ear infection, and sepsis in the very young and elderly.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

GPN Vaccines secures $18 million in Series B led by Forepont Capital, Kern Capital and Shearwater Capital

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information